576 related articles for article (PubMed ID: 23640384)
21. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
22. An outbreak of early-onset endophthalmitis caused by Fusarium species following cataract surgery.
Cakir M; Imamoğlu S; Cekiç O; Bozkurt E; Alagöz N; Oksüz L; Yilmaz OF
Curr Eye Res; 2009 Nov; 34(11):988-95. PubMed ID: 19958115
[TBL] [Abstract][Full Text] [Related]
23. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
Higashiyama T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ohji M
Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
[TBL] [Abstract][Full Text] [Related]
24. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
25. Combined therapy with intravitreal bevacizumab and posterior subtenon triamcinolone acetonide injection in diabetic macular oedema.
Kim HD; Kang KD; Choi KS; Rhee MR; Lee SJ
Acta Ophthalmol; 2014 Nov; 92(7):e589-90. PubMed ID: 24866832
[No Abstract] [Full Text] [Related]
26. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
[No Abstract] [Full Text] [Related]
27. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R
Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.
Parrozzani R; Pilotto E; Dario A; Miglionico G; Midena E
Am J Ophthalmol; 2013 Jan; 155(1):127-133.e2. PubMed ID: 22995029
[TBL] [Abstract][Full Text] [Related]
29. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
[TBL] [Abstract][Full Text] [Related]
30. Comparison of a single intravitreal injection of bevacizumab versus triamcinolone acetonide as primary treatment for diffuse diabetic macular oedema.
Penha FM; Maia M; Cardillo JA; Arevalo JF; Wu L; Rodriguez FJ; Berrocal MH; Farah ME;
Acta Ophthalmol; 2012 Mar; 90(2):e160-1. PubMed ID: 21470386
[No Abstract] [Full Text] [Related]
31. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor.
Mezad-Koursh D; Goldstein M; Heilwail G; Zayit-Soudry S; Loewenstein A; Barak A
Retina; 2010; 30(7):1051-7. PubMed ID: 20616683
[TBL] [Abstract][Full Text] [Related]
32. Combined intravitreal pharmacosurgery in patients with occult choroidal neovascularization secondary to wet age-related macular degeneration.
Koss MJ; Scholtz S; Haeussler-Sinangin Y; Singh P; Koch FH
Ophthalmologica; 2010; 224(2):72-8. PubMed ID: 19707030
[TBL] [Abstract][Full Text] [Related]
33. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
34. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection.
Chaudhary KM; Romero JM; Ezon I; Fastenberg DM; Deramo VA
Retina; 2013; 33(7):1407-16. PubMed ID: 23492945
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
[TBL] [Abstract][Full Text] [Related]
36. Acute endophthalmitis after intravitreal injection and preventive effect of preoperative topical antibiotics.
Park Y; Kim KS; Park YH
J Ocul Pharmacol Ther; 2013 Dec; 29(10):900-5. PubMed ID: 24067061
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
[TBL] [Abstract][Full Text] [Related]
38. Combined intravitreal bevacizumab and triamcinolone acetonide injection for idiopathic neuroretinitis.
Cakir M; Cekiç O; Bozkurt E; Pekel G; Yazici AT; Yilmaz OF
Ocul Immunol Inflamm; 2009; 17(3):221-3. PubMed ID: 19585368
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.
Wang YS; Li X; Wang HY; Zhang ZF; Li MH; Su XN
Chin Med J (Engl); 2011 Feb; 124(3):352-8. PubMed ID: 21362332
[TBL] [Abstract][Full Text] [Related]
40. [Complications of intravitreal injections--own experience].
Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
